Oneness Biotech receives written notification by writing from Taiwan Food and Drug Administration under Letter#1096013906 to allow Phase 3 MRCT of ON101 (protocol#ON101CLCT02) to proceed with 2ndinterim statistical analysis as final results for Phase 3 trial.
關閉
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
